Key statistics
On Friday, Procept Biorobotics Corp (PRCT:NMQ) closed at 84.99, -0.96% below its 52-week high of 85.81, set on Aug 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 83.22 |
---|---|
High | 85.26 |
Low | 82.13 |
Bid | 80.00 |
Offer | 87.00 |
Previous close | 82.79 |
Average volume | 616.85k |
---|---|
Shares outstanding | 51.42m |
Free float | 48.20m |
P/E (TTM) | -- |
Market cap | 4.37bn USD |
EPS (TTM) | -2.06 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
- PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
- PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance
- PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
- PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
- PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
- PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
- Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
- PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
- Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
More ▼